# Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants

> **NCT05213481** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tepotinib
- **DRUG:** Carbamazepine

## Key facts

- **NCT ID:** NCT05213481
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2022-05-06
- **Final completion:** 2022-05-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05213481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05213481, "Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05213481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*